These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37950857)

  • 1. Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory non-Hodgkin lymphoma: A multicenter consensus approach.
    Saifi O; Lester SC; Breen WG; Rule WG; Lin Y; Bennani NN; Rosenthal A; Munoz J; Murthy HS; Kharfan-Dabaja MA; Peterson JL; Hoppe BS
    Am J Hematol; 2024 Jan; 99(1):124-134. PubMed ID: 37950857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.
    Imber BS; Sadelain M; DeSelm C; Batlevi C; Brentjens RJ; Dahi PB; Giralt S; Park JH; Sauter C; Scordo M; Shah G; Perales MA; Palomba ML; Yahalom J
    Br J Haematol; 2020 Jul; 190(1):45-51. PubMed ID: 32135029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy.
    Weinstock M; Elavalakanar P; Bright S; Ambati SR; Brouwer-Visser J; Pourpe S; Fiaschi N; Jankovic V; Thurston G; Deering RP; Chaudhry A; Joyce R; Arnason J
    Br J Haematol; 2022 Nov; 199(3):366-370. PubMed ID: 35892294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric Antigen Receptor T-cell Therapy: Current Status and Clinical Outcomes in Pediatric Hematologic Malignancies.
    Talleur AC; Myers R; Annesley C; Shalabi H
    Hematol Oncol Clin North Am; 2022 Aug; 36(4):701-727. PubMed ID: 35780062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
    Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
    Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma.
    Saifi O; Breen WG; Lester SC; Rule WG; Stish BJ; Rosenthal A; Munoz J; Lin Y; Bansal R; Hathcock MA; Bennani NN; Paludo J; Khurana A; Villasboas JC; Johnston PB; Ansell SM; Iqbal M; Moustafa MA; Murthy HS; Kharfan-Dabaja MA; Hoppe BS; Peterson JL
    Int J Radiat Oncol Biol Phys; 2023 Aug; 116(5):999-1007. PubMed ID: 36563910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
    Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL
    Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Dubnikov Sharon T; Assayag M; Avni B; Kfir-Erenfeld S; Lebel E; Gatt ME; Goldschmidt N; Stepensky P; Asherie N; Grisariu S
    Br J Haematol; 2023 Jul; 202(1):74-85. PubMed ID: 37070396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of radiation in chimeric antigen receptor T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma: Current studies and future prospects.
    Yu L; Zou R; He J; Qu C
    Crit Rev Oncol Hematol; 2024 Jul; 199():104390. PubMed ID: 38782146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
    Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
    Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy.
    Hubbeling H; Silverman EA; Michaud L; Tomas AA; Shouval R; Flynn J; Devlin S; Wijetunga NA; Tringale KR; Batlevi C; Dahi P; Giralt S; Lin R; Park J; Scordo M; Sauter C; Shah G; Hajj C; Salles G; Schoder H; Palomba ML; Perales MA; Yahalom J; Imber BS
    Transplant Cell Ther; 2023 Apr; 29(4):259.e1-259.e10. PubMed ID: 36587744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options.
    Del Toro-Mijares R; Oluwole O; Jayani RV; Kassim AA; Savani BN; Dholaria B
    Br J Haematol; 2023 Apr; 201(1):15-24. PubMed ID: 36709623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas.
    El-Galaly TC; Cheah CY; Kristensen D; Hutchison A; Hay K; Callréus T; Villa D
    Acta Oncol; 2020 Jul; 59(7):766-774. PubMed ID: 32189546
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.
    Iqbal M; Jagadeesh D; Chavez J; Khurana A; Rosenthal A; Craver E; Epperla N; Li Z; Isufi I; Awan FT; Dholaria BR; Maakaron JE; Sandoval-Sus JD; Mishra R; Saha A; Annunzio K; Bhaskar ST; Sumransub N; Fijalka A; Ivanov SA; Lin Y; Kharfan-Dabaja MA
    Bone Marrow Transplant; 2024 Feb; 59(2):211-216. PubMed ID: 37973893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?
    Saifi O; Breen WG; Lester SC; Rule WG; Stish B; Rosenthal A; Munoz J; Herchko SM; Murthy HS; Lin Y; Bansal R; Hathcock MA; Bennani NN; Paludo J; Wang Y; Khurana A; Bisneto JCV; Johnston PB; Ansell SM; Iqbal M; Tun H; Ayala E; Kharfan-Dabaja MA; Hoppe BS; Peterson JL
    Radiother Oncol; 2022 Jan; 166():171-179. PubMed ID: 34890736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD19-directed CART therapy for T-cell/histiocyte-rich large B-cell lymphoma.
    Pophali PA; Fein JA; Ahn KW; Allbee-Johnson M; Ahmed N; Awan FT; Farhan S; Grover NS; Hilal T; Iqbal M; Maakaron J; Modi D; Nasrollahi E; Schachter LG; Sauter C; Hamadani M; Herrera A; Shouval R; Shadman M
    Blood Adv; 2024 Oct; 8(20):5290-5296. PubMed ID: 38985302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
    Roddie C; Dias J; O'Reilly MA; Abbasian M; Cadinanos-Garai A; Vispute K; Bosshard-Carter L; Mitsikakou M; Mehra V; Roddy H; Hartley JA; Spanswick V; Lowe H; Popova B; Clifton-Hadley L; Wheeler G; Olejnik J; Bloor A; Irvine D; Wood L; Marzolini MAV; Domning S; Farzaneh F; Lowdell MW; Linch DC; Pule MA; Peggs KS
    J Clin Oncol; 2021 Oct; 39(30):3352-3363. PubMed ID: 34464155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapy.
    Ababneh HS; Abramson JS; Johnson PC; Patel CG
    Radiother Oncol; 2022 Oct; 175():65-72. PubMed ID: 35952976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma.
    Wright CM; LaRiviere MJ; Baron JA; Uche C; Xiao Y; Arscott WT; Anstadt EJ; Barsky AR; Miller D; LaRose MI; Landsburg DJ; Svoboda J; Nasta SD; Gerson JN; Barta SK; Chong EA; Schuster SJ; Paydar I; Maity A; Plastaras JP
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):178-188. PubMed ID: 32446950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.